Decrease in the efficacy of glucagon-like peptide-1 receptor agonists: what is the reason?

Autor: Kushnarova, N.M., Zinych, O.V., Korpavchev, V.V., Kovalchuk, A.V., Prybyla, O.V., Shyshkan-Shishova, K.O.

Publikováno v: INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine); Vol. 17 No. 8 (2021); 637-645
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 17 № 8 (2021); 637-645
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 17 № 8 (2021); 637-645

The review deals with the drugs of a group of glucagon-like peptide-1 receptors agonists (GLP-1RA) the action of which is based on the incretin effect. In addition to insulinotropic and glucagonostatic action, GLP-1RA contributes to the improvement o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=scientific_p::c207cdc59053fa94866246bd3b69aec6
http://iej.zaslavsky.com.ua/article/view/246799